Cornerstone Robotics (CSR) is an innovative surgical robotics unicorn driven by the vision of leading medical innovations for a healthier world. We advance surgical care with cutting-edge robotic systems to make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centers worldwide, we have established a 30,000-square-meter manufacturing facility in China.
Developed entirely in-house, the Sentire® Endoscopic Surgical System has successfully completed multicenter clinical trials in China and the United Kingdom and has received regulatory approvals in China, the European Union, and Singapore. Indicated for key specialties including general surgery, gynecology, thoracic and urology, the Sentire® System provides advanced minimally invasive surgical solutions to healthcare professionals worldwide, helping expand access to high-quality surgical care and improve patient outcomes globally.
Company History
September Cornerstone Robotics was officially established.
August Completed the Proof-of-Concept.
December Successfully completed dozens of laboratory assessments on cadavers and animal models in Hong Kong.
June Surgical robot prototype successfully tested in porcine model in Shenzhen, China.
November Completed Series B financing round of over USD 75 million. The total amount of financing raised to date is approximately USD 120 million.
June Featured in the showcase of outstanding enterprises for the 25th Anniversary of the Hong Kong Handover and conducted technology demonstration for China’s national leaders.
August Completed the first human clinical trials in urology and general surgery in Hong Kong.
June Completed Series B+ financing round of over US$90 million.
December Successfully completed a multi-center human clinical trial.
June Formed partnership with the Chinese University of Hong Kong, Shenzhen (CUHK-SZ) Medical School to build a world-class surgical robotics training program.
September CSR’s first robotic surgical system, Sentire®, registration approval by China’s National Medical Products Administration (NMPA).
December CSR’s first robotic surgical system, Sentire®, registration approval by China’s National Medical Products Administration (NMPA).
January Completed a Series C funding round of over USD 70 million to support the acceleration of CSR’s R&D and global commercialization plans.
May Starting human clinical trials in the United Kingdom.
July Signed a tripartite strategic cooperation memorandum with the National Health Insurance Group of Singapore and the Lee Kong Chian School of Medicine at Nanyang Technological University.
November Closes New Financing Round of Approximately USD 200 million.
May Sentire® received EU CE (MDR) and Singapore HSA certifications, covering four major specialties: general surgery, gynecology, thoracic and urology.
September Cornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery
Corporate Culture
Forging accessibility and efficiency in robotic surgery and delivering high-quality healthcare to all.
Lead medical innovations for a healthier world.
Cornerstone Robotics (CSR) is dedicated to delivering accessible surgical systems that allow patients around the world to benefit from the high standards of care.
